Introduction
============

Researchers in a variety of areas have demonstrated that n-3 (omega-3) polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), have considerable effects on physiological function. Animal and human studies[@b1-cia-8-1247]--[@b4-cia-8-1247] in addition to epidemiological surveys[@b5-cia-8-1247]--[@b7-cia-8-1247] have also shown that n-3 PUFAs effectively enhance and improve learning capability as well as memory and cognitive function. Moreover, intake of EPA and DHA is reported to reduce the risk of developing Alzheimer's disease.[@b8-cia-8-1247] However, most studies in humans have assessed the effects of n-3 PUFAs based on the results of psychological tests and cognitive tasks. There are very few studies employing physiological methods that target elderly participants, although there are some studies targeting young adults or children.[@b9-cia-8-1247]--[@b13-cia-8-1247]

Fish oil contains abundant amounts of n-3 PUFAs, most of which is stored as triglycerides. Sardine oil is one of the most popular fish oils, and is abundant in n-3 PUFAs incorporated in triglycerides. In some cases, n-3 PUFAs are stored as phospholipids. Krill is the common name given to the order Euphausiacea of shrimp-like plankton. Krill oil is rich in n-3 PUFAs incorporated in phosphatidylcholine. Vakhapova et al[@b14-cia-8-1247] and Richter et al[@b15-cia-8-1247] demonstrated that phosphatidylserine containing n-3 PUFAs was effective for improvement of memory in the elderly. However, the differences in effects on cognitive function between these two forms of storage (ie, phospholipid and triglyceride), have not been clarified.

Among the neuroimaging methods available, near-infrared spectroscopy and event-related potentials are most suitable for measuring changes in brain function longitudinally and noninvasively. Moreover, the devices required are easy to operate and the cost is low compared with other neurophysiological methods. When brain activity is activated locally, the supply of oxygen to that area increases accordingly. Oxygen binds with hemoglobin and is transported in the form of oxyhemoglobin. Therefore, by measuring blood oxyhemoglobin concentrations using near-infrared spectroscopy, it is possible to identify the level of activation of regional cerebral function resulting from the execution of tasks. Near-infrared spectroscopy emits near-infrared light from above the scalp. Analyzing near-infrared light at several wavelengths detected after it has been absorbed by oxyhemoglobin while passing through the tissues of the cerebral cortex makes it possible to measure the relative changes in oxyhemoglobin concentration as a marker of neural activity in the cerebral cortex.[@b16-cia-8-1247] Event-related potentials, obtained by analyzing electroencephalograms (EEGs), represent information processing in the brain electrophysiologically, and are elicited especially while executing cognitive tasks. Among the event-related potential components, P300 is considered to reflect cognitive processes, such as making decisions and controlling behaviors and activities.[@b17-cia-8-1247] Because near-infrared spectroscopy has a relatively high spatial resolution, it is useful for localizing activated areas. The event-related potential, in contrast, has the advantage of high temporal resolution.

In this study, two types of continuous performance tasks were used during measurement of changes in oxyhemoglobin concentration and event-related potentials, ie, the working memory task and the calculation task. The amount of working memory mobilized to perform each task is considerably different. The former needs mobilization of much working memory. On the contrary, the latter demands little working memory. Working memory is a function that serves as the basis of cognitive activity.

Prior to conducting a study with a large sample size, we performed a preliminary examination to clarify the effects of long-term ingestion of krill oil and sardine oil on cognitive function in elderly males using the two neurophysiological methods described previously. Further, we investigated differences in effects of n-3 PUFAs on cognitive function in relation to the different chemical forms of storage. Only male subjects were recruited to participate in this study, because cerebral blood volume changes during cognitive activation have been found to be gender-dependent.[@b18-cia-8-1247] Differences in event-related potentials have also been reported to be gender-dependent.[@b19-cia-8-1247]

Materials and methods
=====================

Subjects
--------

Healthy male subjects in their 60s and 70s who had retired from employment in the Japanese business sector were recruited for this study; all participants were paid volunteers. Eligibility for participation was as follows: right-handedness, not requiring prescription medication, no history of mental disorders or cerebrovascular disease, absence of serious liver, kidney, heart, respiratory, endocrine, or metabolic diseases, and absence of food allergies to fish or crustaceans. The participants were clinically confirmed by a psychiatrist to have no cognitive impairment.

We provided written and oral explanations in advance about the purpose of our study in accordance with the Declaration of Helsinki. All the participants gave their written informed consent to participate in the study protocol, which was approved by the ethics committee of Kyorin University School of Medicine.

The participants were measured for their height, body weight, and blood pressure, and then underwent a blood test (white blood cell count, red blood cell count, hemoglobin, and hematocrit), a serum chemistry test (aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, blood glucose, glycosylated hemoglobin, and uric acid) and urinalysis (occult blood, urinary protein, urinary glucose, and urobilinogen). Forty-five men of mean age (± standard deviation) 67.1 ± 3.4 years with no markedly abnormal findings for these parameters were randomly divided into three treatment groups (n = 15 per group). The participants were instructed to avoid excessive consumption of alcohol and food, to limit strenuous exercise, and to refrain from taking supplements that contained PUFAs during the study.

Experimental supplement
-----------------------

Three types of experimental supplement were used: krill oil as a typical oil rich in PUFAs incorporated in phosphatidylcholine, sardine oil as a typical fish oil, and medium-chain triglycerides as placebo. Each supplement was prepared by Nippon Suisan Kaisha Ltd. [Table 1](#t1-cia-8-1247){ref-type="table"} shows the composition of the main ingredients in the supplements. They were supplied in soft gelatin capsules containing 0.25 g oil per capsule. There was no difference in color, size, form, smell, or taste between the three types of capsules. Subjects were asked to take four capsules twice a day after breakfast and dinner for 12 weeks (eight capsules daily), from the day following the initial measurements to the day of the final measurements. The participants were instructed to complete a self-recorded checklist to document their supplement intake during the study period.

Experimental design
-------------------

A randomized, double-blind, parallel-group, comparative study design was adopted. A computer-generated random allocation sequence was used for participant randomization. This was performed by a person who was not involved with other aspects of the study. Information about assignment was not revealed to the researchers until the key was opened. The participants were not informed about which treatment was included in their capsules. Before the participants started treatment, and at week 6 and week 12, we simultaneously recorded changes in oxyhemoglobin concentration and an EEG during performance of the working memory task, and measured changes in oxyhemoglobin concentration during the calculation task. Near-infrared spectroscopy and EEG recordings were performed in an electrically shielded chamber in the laboratory of the neuropsychiatry division at Kyorin University. The following were also performed: a survey of food intake frequency, measurements of body weight and blood pressure, a blood test, a serum chemistry test, measurements of plasma fatty acids (dihomo-gamma-linolenic acid, arachidonic acid, EPA, and DHA), and urinalysis. Subjects showing any abnormal physical symptoms or findings on blood or urine testing during treatment were withdrawn from the study.

Food frequency method
---------------------

The Food Frequency Questionnaire Based on Food Groups (FFQg, version 3.0, Kenpakusha, Tokyo, Japan) was used to evaluate intake of nutrients during the study period. The FFQg was developed for use in Japan and is based on 29 food groups and 10 types of cooking methods, and is used for estimating energy and nutrient intake per week for the previous month.[@b20-cia-8-1247] From the FFQg, the mean dietary energy intake was calculated according to the fifth revised and enlarged edition of the Standard Tables of Food Composition in Japan.[@b21-cia-8-1247] The participants' responses were obtained by interview. We calculated the intake of energy and of individual nutrients per day (protein, fats, carbohydrates, sodium, potassium, calcium, magnesium, phosphorus, iron, zinc, copper, manganese, dietary fiber, retinol equivalent, vitamin D, alpha-tocopherol, vitamin K, vitamin B~1~, vitamin B~2~, niacin, vitamin B~6~, vitamin B~12~, folic acid, pantothenic acid, vitamin C, saturated fatty acids, monounsaturated fatty acids, PUFAs, n-3 PUFAs, n-6 PUFAs, and cholesterol).

Tasks
-----

### Working memory task

A continuous performance task using the 2-back paradigm was carried out. Numerals from 1 to 9 randomly appeared successively on a computer screen placed 150 cm in front of the participant for 500 msec each, with an interstimulus interval of 2,250 msec. The participants were instructed to push a button with their right thumb when the numeral "3" was displayed only if they recalled that the numeral 2-back was even, and to do nothing when the numeral 2-back was odd. Two hundred numerals were presented in total, with the target "3" numeral being shown at a rate of 10% (20 trials). For 14 seconds before starting to show the stimulus, the numeral "0" was shown on the display monitor for the same duration and interval as the stimulus, and the participants were instructed to watch the numeral carefully. The task lasted 450 seconds.

### Calculation task

A calculation task was conducted using the Uchida-Kraepelin test paper. The participants were asked to add two adjacent numerals and write down only the last numeral of the two-digit number that was obtained. The participants were instructed to make the calculation as quickly and accurately as possible. The task lasted 300 seconds.

Measurement and data analysis
-----------------------------

### Changes in oxyhemoglobin concentration

Changes in oxyhemoglobin concentration while participants performed the tasks were measured using near-infrared spectroscopy (Optical Topography System ETG-4000, Hitachi Medical Co, Tokyo, Japan). We used a two-sided 3 × 3 probe holder, and placed the emitter probes and detector probes at sites where we could measure changes in oxyhemoglobin concentration in each participant's bilateral dorsolateral prefrontal cortex. That is, the front row inner optodes were positioned symmetrically 0.5 cm outside of Fp~1~ or Fp~2~ according to the International EEG 10--20 system, and changes in each participant's oxyhemoglobin concentration were measured from a total of 24 channels ([Figure 1](#f1-cia-8-1247){ref-type="fig"}). Mean changes in oxyhemoglobin concentration were calculated against the mean concentration during a 10-second period for the prestimulus baseline.

### Electroencephalography

While the participants performed the working memory task, we simultaneously measured changes in oxyhemoglobin concentration and event-related potentials. Ag/AgCl electrodes were located at Cz (vertex) and Pz (midline parietal site) according to the International EEG 10--20 system. The EEG was recorded and fltered from 0.1 Hz to 100 Hz, using linked electrodes at the earlobes as the reference. The EEG was recorded for 450 seconds while the participants performed the working memory task. The EEG was averaged off-line for a period of 1,000 msec, beginning 100 msec prior to the stimulus onset. The baseline was corrected to the mean value of the voltage during a period of 100 msec prestimulus. From ten to 20 trials without artifacts due to eye blinking or body movement were averaged to obtain the event-related potential waveform. The peak latency and amplitude of the P300 component of the event-related potential waveform at Cz and Pz were measured. The differential values of P300 latency and amplitude at week 6 and week 12 compared with those at week 0 were calculated for both sites. P300 is the positive potential that appears approximately 300 msec after a stimulus is presented.

Statistical analysis
--------------------

Statistical Package for the Social Sciences version 16.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical processing. Two-way repeated-measures analysis of variance with the Bonferroni post hoc test was carried out on the following near-infrared spectroscopic and other data: change in oxyhemoglobin concentration, body weight, body mass index, blood pressure, blood test values, serum chemistry test values, urinalysis, nutritional intake based on food frequency method, and plasma fatty acid concentration. For P300 latency and amplitude, the Kruskal--Wallis test was used to analyze the differential values measured at week 6 and week 12 compared with those at week 0. The Mann-Whitney *U*-test with Bonferroni correction was then used to determine any differences between the treatments. The statistical significance level was set at *P* \< 0.05.

Results
=======

Participants
------------

A flow chart for study participation is shown in [Figure 2](#f2-cia-8-1247){ref-type="fig"}. As mentioned earlier, 45 males who met the inclusion criteria agreed to participate in this study. They were randomly assigned to three treatment groups. Age, height, body weight, body mass index, smoking status, and alcohol consumption were compared by one-way analysis of variance or the chisquare test. No significant differences were found in any of the items except for height (*F*\[2,42\] = 4.379, *P* = 0.019 by one-way analysis of variance) between the three groups ([Table 2](#t2-cia-8-1247){ref-type="table"}).

Three of the 45 participants dropped out during the study period. Data for 15 participants in the medium-chain triglyceride group, 13 in the krill oil group, and 14 in the sardine oil group were used for analysis. The reasons for dropping out were epigastric pain (two participants) and dermatitis (one participant). These cases were judged not to be directly related to ingestion of supplements.

Supplement intake rate
----------------------

According to the self-recording checklist, mean supplement intake for the experimental period (excluding dropout participants) was 98.2% ± 2.4% in the medium-chain triglyceride group (n = 15), 98.7% ± 1.6% in the krill oil group (n = 13), and 98.5% ± 1.7% in the sardine oil group (n = 14). No significant difference in intake was found between the three groups (*F*\[2,39\] = 0.181, *P* = 0.835 by one-way analysis of variance).

Food frequency questionnaire, vital signs, and blood and urine tests
--------------------------------------------------------------------

No significant differences between the treatments or ingestion periods were found with regard to any of the nutrients measured by the food frequency method, such as amounts of major components ingested or dietary fatty acids and cholesterol. No harmful events due to the treatments were observed in any of the treatment groups during the study. None of the groups showed any significant variations in body weight, body mass index, or blood pressure during the study period. Moreover, no changes attributable to ingestion of the supplements were observed in blood tests, serum chemistry tests, or urinalysis.

Plasma fatty acids
------------------

With regard to the concentration of PUFAs in plasma ([Table 3](#t3-cia-8-1247){ref-type="table"}), significant interactions were found between the treatments and ingestion periods in terms of dihomo-gamma-linolenic acid concentration (*F*\[4,78\] = 3.516, *P* = 0.011 by two-way repeated-measures analysis of variance) and EPA concentration (*F*\[4,78\] = 5.141, *P* = 0.001 by two-way repeated-measures analysis of variance). Further analysis using Bonferroni post hoc testing showed that the EPA concentration in the sardine oil group was higher than that in the medium-chain triglyceride group at week 12 (*P* = 0.045).

Working memory task
-------------------

### Changes in oxyhemoglobin concentration

[Figure 3](#f3-cia-8-1247){ref-type="fig"} shows a comparison of changes in oxyhemoglobin concentration at 225.0 seconds after the start of executing the task. With regard to changes in oxyhemoglobin concentration in response to performance of the working memory task, the results of two-way repeated-measures analysis of variance showed a significant interaction in channel 10 (*F*\[4,78\] = 4.331, *P* = 0.003 by two-way repeated-measures analysis of variance). Compared with the medium-chain triglyceride group, the sardine oil group (*P* = 0.043) and the krill oil group (*P* = 0.004) showed significantly greater changes in oxyhemoglobin concentrations at week 12 ([Figure 4](#f4-cia-8-1247){ref-type="fig"}).

### Event-related potentials

[Figure 5](#f5-cia-8-1247){ref-type="fig"} shows the changes in P300 latency and amplitude at Cz and Pz. There were slight differences in the differential values for P300 latency between the treatments at week 6 (Cz, *χ*^2^ = 4.981, *df* = 2, *P* = 0.083; Pz, *χ*^2^ = 5.130, *df* = 2, *P* = 0.077, Kruskal--Wallis test). At week 12 of the ingestion period, there were differences between the groups (Cz, *χ*^2^ = 6.118, *df* = 2, *P* = 0.047; Pz, *χ*^2^ = 5.754, *df* = 2, *P* = 0.056, Kruskal--Wallis test), and a significant difference was observed between the krill oil and medium-chain triglyceride groups (Cz, *P* = 0.027 and Pz, *P* = 0.030, Mann--Whitney *U*-test with Bonferroni correction). Both sites showed no significant difference between treatments for differential values in P300 amplitude at either week 6 or week 12.

Calculation task
----------------

[Figure 6](#f6-cia-8-1247){ref-type="fig"} shows the mean changes in oxyhemoglobin concentration at 150.0 seconds after starting the task. For changes in oxyhemoglobin concentration in response to execution of the calculation task, the results of two-way repeated-measures analysis of variance showed a slight interaction between the treatments and ingestion periods at channel 15 (*F*\[4,78\] = 2.236, *P* = 0.073 by two-way repeated-measures analysis of variance). The krill oil group showed significantly greater changes in oxyhemoglobin concentration compared with the medium-chain triglyceride group at week 12 (*P* = 0.006, [Figure 7](#f7-cia-8-1247){ref-type="fig"}).

Discussion
==========

The results of the working memory tasks show that the groups taking krill oil or sardine oil for 12 weeks had greater changes in oxyhemoglobin concentration in channel 10 than the group taking medium-chain triglycerides. With regard to the effect of n-3 PUFAs, Jackson et al have already demonstrated in their pilot study using near-infrared spectroscopy that supplementation with DHA-rich fish oil, in comparison with placebo, resulted in significantly increased oxyhemoglobin concentrations in the prefrontal areas in healthy young adults.[@b13-cia-8-1247] As the function of the cerebral cortex declines with age, a smaller increase is observed in oxyhemoglobin concentrations resulting from execution of cognitive tasks.[@b18-cia-8-1247],[@b22-cia-8-1247] Near-infrared spectroscopy probes including channel 10 were placed to measure the function of the dorsolateral prefrontal cortex in the present study. The dorsolateral prefrontal cortex performs a variety of functions. Among these, mobilization of working memory is one of the important functions of the dorsolateral prefrontal cortex.[@b23-cia-8-1247]--[@b25-cia-8-1247] Aging reduces regional cerebral blood flow, which causes deterioration of cerebral function.[@b26-cia-8-1247] Aging has also been shown to reduce the level of dorsolateral prefrontal cortex activity during execution of working memory tasks.[@b27-cia-8-1247] The results of this study suggest that long-term ingestion of krill oil and sardine oil promotes working memory function by activating the dorsolateral prefrontal cortex in elderly people, and thus prevents deterioration in cognitive activity.

Very few studies have been published using the event-related potential to identify the effects of EPA and DHA. Fontani et al compared event-related potential measurements while subjects executed the Go/No-Go paradigm before and after taking fish oil for 35 days, and reported improvement in attentional functions after ingestion of n-3 PUFAs.[@b9-cia-8-1247] Regarding P300, which was measured simultaneously with near-infrared spectroscopy recording, we observed no differences in amplitude between our treatment groups, although the group that took krill oil for 12 weeks showed a significant decrease in latency compared with the medium-chain triglyceride group. P300 latency is thought to reflect the rate of information processing, while amplitude is thought to reflect the amount of mobilization of processing resources.[@b28-cia-8-1247] Continuous ingestion of krill oil was thus shown to expedite the information processing rate. P300 latency is known to be prolonged with aging,[@b29-cia-8-1247],[@b30-cia-8-1247] ie, ingestion of krill oil is likely to ameliorate the reduction of cerebral function associated with aging, or to maintain such function.

During the calculation tasks, the krill oil group showed significantly greater changes in oxyhemoglobin concentrations in the left frontal area (channel 15) as compared with changes seen in the medium-chain triglyceride group. The left hemisphere of the brain is generally regarded to be dominant with respect to performing calculations. Our results suggest that intake of krill oil enhances the function of the cerebral hemisphere relating to calculation. A considerable decrease in oxyhemoglobin concentration changes at week 12 was observed for both tasks in the medium-chain triglyceride group. Although the reason for these results is unclear, there is a possibility that the practice effect was emphasized only in the medium-chain triglyceride condition.

Physiological measurement by near-infrared spectroscopy and EEG analyses demonstrated that krill oil and sardine oil have the effect of activating the function of the cerebral cortex. No difference was found between the three groups in terms of food-derived fatty acid intake volume. Therefore, the effects obtained in the krill oil and sardine oil groups are considered to result from ingestion of the supplements.

Both krill oil and sardine oil were shown to promote activity of the dorsolateral prefrontal cortex in terms of the working memory task. Given that these supplements contain EPA and DHA, which are not contained in medium-chain t riglycerides, these fatty acids were assumed to have influenced the activity of the dorsolateral prefrontal cortex. However, sardine oil, which contains the largest amounts of these fatty acids, was not shown to possess any activation effects regarding the calculation task, and only krill oil, containing lesser amounts of these fatty acids, was shown to have an effect. The fatty acids contained in fish oil are usually stored as triglycerides. Krill oil, in contrast, has a far higher percentage of phospholipids, in particular phosphatidylcholine, than other foods.[@b31-cia-8-1247]--[@b34-cia-8-1247] Most of the n-3 PUFAs contained in krill oil are thought to be incorporated in phosphatidylcholine. In this study, krill oil had a lower EPA and DHA content than sardine oil. Plasma EPA concentrations in the sardine oil group were significantly higher than in the medium-chain triglyceride group at week 12. On the other hand, there was no significant difference in plasma EPA concentration between the krill oil and medium-chain triglyceride groups. Nevertheless, krill oil demonstrated effects that were equivalent to or better than those of sardine oil. This led us to assume that the difference in their chemical form of incorporation was the reason for the different effects between the two oils rather than any difference in their fatty acid content.

Vaisman et al reported that ingestion of phospholipid-conjugated EPA and DHA increased the scores for a continuous performance task compared with scores obtained when the fatty acids in the ingested oil were stored as triglycerides. This finding indicates that n-3 PUFAs incorporated in phosphatidylcholine act on brain function more efficiently than those incorporated in triglycerides.[@b35-cia-8-1247] Brossard et al[@b36-cia-8-1247] and Lemaitre-Delaunay et al[@b37-cia-8-1247] reported that lysophosphatidylcholine, which is derived from phosphatidylcholine by phospholipase A~2~, is the preferred physiological carrier of DHA. Thies et al found that PUFAs bound to lysophospholipids at the sn-2 position are preferentially incorporated into the brain.[@b38-cia-8-1247] PUFAs are most often bound to the sn-2 position in phospholipids.[@b39-cia-8-1247] The n-3 PUFAs bound to phosphatidylcholine in krill oil may thus be taken up by the brain tissues more readily than the n-3 PUFAs of sardine oil, most likely bringing about the observed difference in their effects. However, the relationship between brain function and fatty acid composition in brain tissue has not been clarified, so further studies need to be carried out.

The major limitations of the present study are its small sample size and inclusion of male subjects only. However, its results suggest that n-3 PUFAs activate cognitive function of the brain in the elderly. The differences in the effects obtained by krill oil and sardine oil seem to be related to differences with regard to incorporation of fatty acids into lipids. It is concluded that fatty acids present as phosphatidylcholine have the potential to bring about more beneficial effects on cognitive function. Further studies using large sample sizes and including female subjects are needed to confirm the results of this study.

We thank the volunteers who participated in this study.
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![Channel positions for near-infrared spectroscopy. Changes in oxyhemoglobin concentration were measured at 24 sites in the bilateral frontal areas of the brain. Filled (black) circles and open (white) circles show the emitter and detector probes, respectively. The numbers show the location of the measured channels.](cia-8-1247Fig1){#f1-cia-8-1247}

![Flow chart of participation throughout the study.\
**Abbreviations:** MCTs, medium-chain triglycerides; KO, krill oil; SO, sardine oil.](cia-8-1247Fig2){#f2-cia-8-1247}

![Topographic maps of changes in oxyhemoglobin concentration at 225.0 seconds during working memory task.\
**Note:** MCT, n = 15; KO, n = 13; SO, n = 14.\
**Abbreviations:** MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil.](cia-8-1247Fig3){#f3-cia-8-1247}

![Comparison of changes in oxyhemoglobin (oxy-Hb) concentrations at channel 10 during working memory task.\
**Notes:** Values are expressed as the group mean ± standard error. MCT, n = 15; KO, n = 13; SO, n = 14. Values were significantly different from the MCT group. \**P* \< 0.05, \*\**P* \< 0.01 by Bonferroni post hoc test.\
**Abbreviations:** MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil.](cia-8-1247Fig4){#f4-cia-8-1247}

![Comparison of differential values in P300 latencies and amplitudes during the working memory task. (**A**) Latency at Cz, (**B**) latency at Pz, (**C**) amplitude at Cz, and (**D**) amplitude at Pz.\
**Notes:** Values are expressed as the group mean ± standard error. MCT, n = 15; KO, n = 13; SO, n = 14. Values were significantly different from the MCT group: \**P* \< 0.05 by Mann-Whitney *U*-test with Bonferroni correction. No significant difference in P300 amplitude was observed between the treatments at week 6 or week 12.\
**Abbreviations:** MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil.](cia-8-1247Fig5){#f5-cia-8-1247}

![Topographic maps of changes in oxyhemoglobin concentration at 150.0 seconds during the calculation task.\
**Note:** MCT, n = 15; KO, n = 13; SO, n = 14.\
**Abbreviations:** MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil.](cia-8-1247Fig6){#f6-cia-8-1247}

![Comparison of changes in oxyhemoglobin (oxy-hb) concentration at channel 15 during the calculation task.\
**Notes:** Values are expressed as the group mean ± standard error. MCT, n = 15; KO, n = 13; SO, n = 14. Values were significantly different from the MCT group: \*\**P* \< 0.01 by Bonferroni post hoc tests.\
**Abbreviations:** MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil.](cia-8-1247Fig7){#f7-cia-8-1247}

###### 

Composition of each supplement (per daily dose)

  Nutrients                                MCTs     KO      SO
  ---------------------------------------- -------- ------- ------
  Components                                                
   Water (g)                               \<0.02   Trace   0
   Total lipids (g)                        1.98     1.98    1.98
   Tocopherol (mg)                         0        14      20
  Lipid class                                               
   Phospholipids in total lipids (g)       0        0.90    0
  Fatty acid composition of total lipids                    
   8:0 (mg)                                1,497    13      0
   10:0 (mg)                               287      7       0
   12:0 (mg)                               5        5       0
   14:0 (mg)                               0        155     84
   14:1 (mg)                               0        4       0
   15:0 (mg)                               0        7       3
   16:0 (mg)                               0        280     106
   16:1 (mg)                               0        87      148
   16:2 (mg)                               0        9       27
   16:3 (mg)                               0        3       44
   16:4 (mg)                               0        11      77
   17:0 (mg)                               0        35      5
   17:1 (mg)                               0        4       0
   18:0 (mg)                               0        19      9
   18:1 (mg)                               13       249     154
   18:2n-6 (mg)                            4        25      22
   18:3n-3 (mg)                            0        13      14
   18:4n-3 (mg)                            0        34      82
   20:1 (mg)                               0        11      3
   20:2n-6 (mg)                            0        0       2
   20:3n-6 (mg)                            0        0       3
   20:4n-6 (mg)                            0        3       20
   20:4n-3 (mg)                            0        4       17
   20:5n-3 (EPA) (mg)                      0        193     491
   21:5n-3 (mg)                            0        5       19
   22:0 (mg)                               0        0       3
   22:1 (mg)                               0        12      0
   22:5n-6 (mg)                            0        0       5
   22:5n-3 (mg)                            0        5       46
   22:6n-3 (DHA) (mg)                      0        92      251
   Unidentifiable (mg)                     0        70      54

**Note:** Subjects took four capsules (0.25 g oil/capsule) twice a day after breakfast and dinner.

**Abbreviations:** MCTs, medium-chain triglycerides; KO, krill oil; SO, sardine oil; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

###### 

Baseline characteristics of the participants

  ------------------------------------------------------------------------
                     MCT\          KO\           SO\           *P*-value
                     (n = 15)      (n = 15)      (n = 15)      
  ------------------ ------------- ------------- ------------- -----------
  Age (years)        67.3 ± 3.4    67.1 ± 3.7    67.0 ± 3.3    0.962

  Height (cm)        167.0 ± 3.9   163.5 ± 5.8   168.6 ± 4.5   0.019

  Body weight (kg)   66.2 ± 10.7   64.9 ± 8.3    63.0 ± 5.9    0.604

  BMI (kg/m^2^)      23.7 ± 3.5    22.8 ± 2.6    23.6 ± 2.2    0.666

  Current smoker     1 (7)         2 (13)        4 (27)        0.306

  Alcohol consumer   11 (73)       13 (87)       12 (80)       0.659
  ------------------------------------------------------------------------

**Notes:** Mean ± standard deviation or n (%). *P*-values derived by one-way analysis of variance or chi-square test.

**Abbreviations:** MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil; BMI, body mass index.

###### 

Polyunsaturated fatty acids in plasma

                 Week 0       Week 6       Week 12      *P*-value                                                                          
  -------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------- --------------- ------------- -------
  DGLA (μg/mL)   25.3 ± 2.5   21.1 ± 2.6   27.3 ± 2.1   25.4 ± 2.1   19.5 ± 1.8   23.4 ± 1.8   25.8 ± 2.4    19.9 ± 2.1      20.0 ± 2.0    0.011
  AA (μg/mL)     156 ± 8      130 ± 5      143 ± 8      158 ± 8      136 ± 6      152 ± 7      159 ± 10      128 ± 7         141 ± 7       0.700
  EPA (μg/mL)    110 ± 10     122 ± 20     99 ± 10      113 ± 12     155 ± 21     155 ± 14     108 ± 12^a^   125 ± 18^a,b^   157 ± 12^b^   0.001
  DHA (μg/mL)    192 ± 14     191 ± 19     191 ± 16     196 ± 14     196 ± 17     205 ± 15     177 ± 13      179 ± 19        187 ± 15      0.944

**Notes:** Mean ± standard error. MCT, n = 15; KO, n = 13; SO, n = 14. *P*-values show significant probability of interaction between treatments and ingestion periods derived by two-way repeated-measures analysis of variance. Numerical values within the same period given different superscript letters (^a^ and ^b^) show significant differences between treatments (*P* \< 0.05 by Bonferroni post hoc test).

**Abbreviations:** DGLA, dihomo-gamma-linolenic acid (20:3n-6); AA, arachidonic acid (20:4n-6); EPA, eicosapentaenoic acid (20:5n-3); DHA, docosahexaenoic acid (22:6n-3); MCT, medium-chain triglyceride; KO, krill oil; SO, sardine oil.
